Viracta lays off 23% of staff, pauses program to slim down for race to finish line in lymphoma

[cafead]

via Viracta Therapeutics is going all-in on its lymphoma program. The biotech responded to phase 2 data by throwing its resources behind a plan to file for a blood cancer approval in 2026, hitting pause on its solid tumor program and putting 23% of its staff out of a job in the process.

article source